A Chimeric Sudan Virus-Like Particle Vaccine Candidate Produced by a Recombinant Baculovirus System Induces Specific Immune Responses in Mice and Horses

Wu, Fangfang; Zhang, Shengnan; Zhang, Ying; Mo, Ran; Yan, Feihu; Wang, Hualei; Wong, Gary; Chi, Hang; Wang, Tiecheng; Feng, Na; Gao, Yuwei; Xia, Xianzhu; Zhao, Yongkun; Wang, Cuiling

doi:10.3390/v12010064

Cited by 7 publications

(4 citation statements)

References 36 publications

(13 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The full-length gene-encoding structural matrix protein (VP40) and glycoprotein (GP) of Sudan virus were cloned in the pFastBacDual vector to yield recombinant bacmids, i.e., pFastBacDual-VP40-VP40 and pFastBacDual-GP-GP, respectively. The transfection and co-expression of recombinant bacmids in Sf-9 cells led to the production of immunogenic Sudan VLPs, which elicited the production of neutralizing antibodies and Th1 (T helper 1)- and Th2 (T helper 2)-type cytokine-secreting immune cells in mice models [ 124 ]. Wang et al [ 125 ] have demonstrated the potential of the baculovirus expression system in the elevated production of human papillomavirus (HPV) L1 capsid protein-based VLPs.…”

Section: Expression Platforms and Upstream Process Development Of Chi...mentioning

confidence: 99%

Challenges and Opportunities in the Process Development of Chimeric Vaccines

Chauhan,

Khasa

2023

Vaccines

View full text Add to dashboard Cite

Vaccines are integral to human life to protect them from life-threatening diseases. However, conventional vaccines often suffer limitations like inefficiency, safety concerns, unavailability for non-culturable microbes, and genetic variability among pathogens. Chimeric vaccines combine multiple antigen-encoding genes of similar or different microbial strains to protect against hyper-evolving drug-resistant pathogens. The outbreaks of dreadful diseases have led researchers to develop economical chimeric vaccines that can cater to a large population in a shorter time. The process development begins with computationally aided omics-based approaches to design chimeric vaccines. Furthermore, developing these vaccines requires optimizing upstream and downstream processes for mass production at an industrial scale. Owing to the complex structures and complicated bioprocessing of evolving pathogens, various high-throughput process technologies have come up with added advantages. Recent advancements in high-throughput tools, process analytical technology (PAT), quality-by-design (QbD), design of experiments (DoE), modeling and simulations, single-use technology, and integrated continuous bioprocessing have made scalable production more convenient and economical. The paradigm shift to innovative strategies requires significant attention to deal with major health threats at the global scale. This review outlines the challenges and emerging avenues in the bioprocess development of chimeric vaccines.

show abstract

Section: Expression Platforms and Upstream Process Development Of Chi...mentioning

confidence: 99%

Challenges and Opportunities in the Process Development of Chimeric Vaccines

Chauhan,

Khasa

2023

Vaccines

View full text Add to dashboard Cite

show abstract

“…Similarly, a trivalent vaccine against three types of zoonotic equine encephalitis virus was shown to produce complete protective immunity upon viral challenge in mice [48]. In 2019, an Ebola virus VLP vaccine candidate, with the matrix structural protein of the Sudan virus as the antigen, was produced in insect cells using the baculovirus expression system [49]. The VLP vaccine elicited B and T cell immune responses in vivo and is another example of the versatility of VLPs.…”

Section: Virus-like Particlesmentioning

confidence: 99%

Biomaterials, biological molecules, and polymers in developing vaccines

Ravi

Shamiya

Chakraborty

et al. 2021

Trends in Pharmacological Sciences

View full text Add to dashboard Cite

Vaccines have been used to train the immune system to recognize pathogens, and prevent and treat diseases, such as cancer, for decades. However, there are continuing challenges in their manufacturing, large-scale production, and storage. Some of them also show suboptimal immunogenicity, requiring additional adjuvants and booster doses. As an alternate vaccination strategy, a new class of biomimetic materials with unique functionalities has emerged in recent years. Here, we explore the current bioengineering techniques that make use of hydrogels, modified polymers, cell membranes, self-assembled proteins, virus-like particles (VLPs), and nucleic acids to deliver and develop biomaterial-based vaccines. We also review design principles and key regulatory issues associated with their development. Finally, we critically assess their limitations, explore approaches to overcome these limitations, and discuss potential future applications for clinical translation. Vaccines and their limitationsSeveral prophylactic and therapeutic vaccines (see Glossary) are successfully used to protect humans against numerous infectious pathogens and diseases, and to prevent their spread among communities worldwide. According to the WHO, more than 70% of children were given shots of routinely administered vaccines (Box 1) globally in 2019 i . Efforts are continuously being made to develop new vaccines for emerging and established pathogens and diseases, the current Coronavirus 2019 (COVID-19) pandemic being a good example. The area of therapeutic vaccine development, particularly for cancer therapy, is also being widely studied [1]. With an increasing demand for high-quality vaccines, there is a need to investigate innovative and novel approaches that are superior to conventional methods (Box 1). Polymer-based nanoparticles (NPs) and nanostructured materials could aid these efforts owing to their favorable characteristics and widespread success in other fields [1][2][3][4]. These NPs can be used to address the current limitations of traditional vaccines, such as low immunogenicity, safety issues, and need for booster doses [5][6][7][8][9]. Here, we discuss different approaches used to elevate the efficacy of vaccines for multiple applications using the principles of engineering (Figure 1, key figure). Engineered biological and biomaterial vaccinesThe engineering of diverse biomaterials, organisms, and biological molecules can yield improved vaccines and vaccine delivery vehicles that overcome several, if not all, of the current limitations and challenges in the field of vaccine development [10]. The following are six approaches using polymeric hydrogels, biologically modified polymers, cell membranes, self-assembled proteins, VLPs, and nucleic acids that have been applied to advance the efficacy and competence of vaccines. The first three approaches make use of the properties of the materials to enhance the delivery of the encapsulated antigens, and the latter three exploit the properties of the biological molecules to develop superior a...

show abstract

“…These viruses have been known since 1911, and some members were successfully developed as biocontrol agent against agricultural and forest insect pests. Baculoviruses have also been developed as vectors for the expression of exogenous genes employed in a variety of sectors such as the pharmaceutical, medical and biotechnological [2,3]. Baculoviridae is divided into 4 genera, Alphabaculovirus (lepidopteran Nucleopolyhedroviruses), Betabaculovirus (lepidopteran Granuloviruses), Gammabaculovirus (hymenopteran NPVs) and Deltabaculovirus (dipteran NPVs) [4].…”

Section: Introductionmentioning

confidence: 99%

Genome sequence analysis of a Helicoverpa armigera single nucleopolyhedrovirus (HearNPV-TR) isolated from Heliothis peltigera in Turkey

et al. 2020

View full text Add to dashboard Cite

The entire genome of Helicoverpa armigera single nucleopolyhedrovirus (HearNPV-TR) was sequenced, and compared to genomes of other existing isolates. HearNPV-TR genome is 130.691 base pairs with a 38.9% G+C content and has 137 open reading frames (ORFs) of � 150 nucleotides. Five homologous repeated sequences (hrs) and two baculovirus repeated ORFs (bro-a and bro-b) were identified. Phylogenetic analysis showed that HearNPV-TR is closer to HaSNPV-C1, HaSNPV-G4, HaSNPV-AU and HasNPV. However, there are significant differences in hr3, hr5 regions and in bro-a gene. Pairwise Kimura-2 parameter analysis of 38 core genes sequences of HearNPV-TR and other Helicoverpa NPVs showed that the genetic distances for these sequences were below 0.015 substitutions/site. Genomic differences as revealed by restriction profiles indicated that hr3, hr5 regions and bro-a gene may play a role in the virulence of HearNPV-TR.

show abstract

A Chimeric Sudan Virus-Like Particle Vaccine Candidate Produced by a Recombinant Baculovirus System Induces Specific Immune Responses in Mice and Horses

Abstract: Viruses 2020, 12, 64 2 of 15 development against SUDV infection. Further, these horse anti-SUDV purified immunoglobulins lay a foundation for SUDV therapeutic drug research.

Cited by 7 publications

References 36 publications

Challenges and Opportunities in the Process Development of Chimeric Vaccines

Challenges and Opportunities in the Process Development of Chimeric Vaccines

Biomaterials, biological molecules, and polymers in developing vaccines

Genome sequence analysis of a Helicoverpa armigera single nucleopolyhedrovirus (HearNPV-TR) isolated from Heliothis peltigera in Turkey

Contact Info

Product

Resources

About